Приказ основних података о документу
Hyperhomocysteinemia and smoking in primary antiphospholipid syndrome
dc.creator | Becarević, Mirjana | |
dc.creator | Mirković, Duško | |
dc.creator | Majkić-Singh, Nada | |
dc.date.accessioned | 2019-09-02T11:15:46Z | |
dc.date.available | 2019-09-02T11:15:46Z | |
dc.date.issued | 2009 | |
dc.identifier.issn | 1452-8258 | |
dc.identifier.uri | https://farfar.pharmacy.bg.ac.rs/handle/123456789/1161 | |
dc.description.abstract | The thrombotic tendency in anti phospholipid syndrome (APS) shares several pathways with atherosclerosis. Atherothrombosis (atherosclerosis superimposed with thromboses) is influenced by nonmodifiable and some modifiable risk factors (smoking, obesity, physical inactivity, alcohol abuse, hyperhomocysteinemia). Therefore, we investigated the association among clinical and serological features of patients with primary APS and potentially modifiable risk factors for the development of atherothrombosis. Also, we compared the analyzed parameters with those in control subjects. Homo cysteine concentrations were detected by HPLC (high performance liquid chromatography), while antiphospholipid antibodies were detected by ELISA. Smokers had elevated levels of homocysteine (chi(2) = 6.22, p lt 0.05). Independently of patients' age, the association between increased levels of homocysteine and history of myocardial infarctions was found (chi(2) = 4.61, p lt 0.05). Hyperhomocysteinemia and smoking are the most important modifiable risk factors for atherothrombosis in primary APS. | en |
dc.publisher | Društvo medicinskih biohemičara Srbije, Beograd i Versita | |
dc.relation | info:eu-repo/grantAgreement/MESTD/MPN2006-2010/145010/RS// | |
dc.rights | openAccess | |
dc.source | Journal of Medical Biochemistry | |
dc.subject | hyperhomocysteinemia | en |
dc.subject | smoking | en |
dc.subject | primary antiphospholipid syndrome | en |
dc.subject | myocardial infarction | en |
dc.title | Hyperhomocysteinemia and smoking in primary antiphospholipid syndrome | en |
dc.type | article | |
dc.rights.license | ARR | |
dcterms.abstract | Бецаревић, Мирјана; Мирковић, Душко; Мајкић-Сингх, Нада; | |
dc.citation.volume | 28 | |
dc.citation.issue | 3 | |
dc.citation.spage | 172 | |
dc.citation.epage | 175 | |
dc.citation.other | 28(3): 172-175 | |
dc.citation.rank | M52 | |
dc.identifier.wos | 000270991100005 | |
dc.identifier.doi | 10.2478/v10011-009-0019-6 | |
dc.identifier.scopus | 2-s2.0-70350655630 | |
dc.identifier.fulltext | https://farfar.pharmacy.bg.ac.rs//bitstream/id/129/1159.pdf | |
dc.type.version | publishedVersion |